ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Jazz acquires neuroscience company Cavion for $52.5 million

by Ryan Cross
August 24, 2019 | APPEARED IN VOLUME 97, ISSUE 33

 

09733-buscon16-cx8998.jpg

Jazz Pharmaceuticals has acquired the neuroscience drug firm Cavion for $52.5 million up front. Cavion’s most advanced drug candidate is a small molecule licensed from Merck & Co. Called CX–8998, it targets T-type calcium channels, which are implicated in several neurological diseases, including essential tremor, epilepsy, and Parkinson’s. Cavion has already tested the compound in clinical trials for those three conditions. Cavion shareholders could earn an additional $260 million in milestone payments as the compound undergoes further testing.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment